trending Market Intelligence /marketintelligence/en/news-insights/trending/v9ql2XYw5-LStFTEFGa05w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca, Seres to research microbiome's role in cancer immunotherapy

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AstraZeneca, Seres to research microbiome's role in cancer immunotherapy

AstraZeneca PLC has formed a research partnership with Seres Therapeutics Inc. to study the microbiome's possible role in improving the efficacy of certain cancer treatments such as those developed by the U.K. pharmaceutical giant.

Cambridge, Mass.-based Seres will receive $20 million over two years and financial support for research activities in the collaboration, according to a March 11 press release.

The research will explore microbiome-based approaches to predict which patients will respond best to certain cancer immunotherapies. Seres said the research may also include the company's investigational microbiome therapy SER-401 in combination with some of AstraZeneca's cancer medicines.

Early pre-clinical research suggests that the gastrointestinal microbiome may have an impact on a patient's clinical response to certain cancer therapies known as checkpoint inhibitor immunotherapies. Seres said this research suggests that modifying the microbiome could improve cancer therapy outcomes.

Seres will continue to hold the rights to its microbiome therapeutic candidates, and AstraZeneca will have the option to negotiate for rights to the programs and other inventions that may result from the collaboration.